Caroline Thielen

Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.

Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018.